Antimicrobial resistance (AMR) is emerging as a major threat to human health worldwide. Whole-genome sequencing (WGS) holds great potential for rapidly and accurately detecting AMR from genomic data in the diagnostic laboratory setting. However, most work to date has focussed on identifying only horizontally-acquired AMRconferring genes, with chromosomally-encoded AMR determinants remaining largely undetected. Here, we present an improved tool for Antibiotic Resistance Detection and Prediction (ARDaP) from WGS data. ARDaP was designed with three priorities: 1) to accurately identify a wide range of AMR genetic determinants (i.e. horizontallyacquired gene gain, single-nucleotide polymorphisms, insertionsdeletions, copy-number variation, and functional gene loss); 2) to predict enigmatic AMR determinants based on novel mutants with moderate-or high-consequence impacts in known AMR-conferring genes, and 3) to detect minor AMR allelic determinants in mixed (e.g. metagenomic) sequence data. ARDaP performance was demonstrated in the melioidosis pathogen, Burkholderia pseudomallei, due to its exclusively chromosomally-encoded AMR determinants and inherently limited treatment options. Using a well-characterised collection of 1,063 clinical strains, ARDaP accurately detected all currently known AMR determinants in B. pseudomallei ( 50 determinants), including stepwise AMR mutations. Additionally, ARDaP accurately predicted meropenem resistance in four previously uncharacterised B. pseudomallei isolates. In mixed strain data, ARDaP identified AMR determinants down to 5% allelic frequency, enabling the early detection of emerging AMR. We demonstrate that ARDaP is an accurate tool for identifying and predicting all confirmed B. pseudomallei AMR determinants from WGS data, including from mixed strain data. Finally, our study illustrates that manual cataloguing and functional verification of putative AMR determinants in individual pathogens is essential for truly comprehensive AMR detection. ARDaP is open source and available at: github.com/dsarov/ARDaP
tion and Prediction from WGS data, which has been designed cilitated genomic-[6, 26] and transcriptomic-[25] based ap-95 proaches for the personalised diagnosis and treatment of AMR 96 infections [27] , and has enabled coordinated, near-real-time 97 AMR surveillance on a global scale [3] . Here, we developed 98 a new bioinformatic tool, ARDaP, to enable the detection 99 of both horizontally-acquired AMR genes via the Compre-100 hensive Antibiotic Resistance Database (CARD) [3, 28] , and 101 chromosomally-encoded AMR determinants encoded by SNPs, 102 indels, CNVs, and gene loss/truncation from WGS data. We 103 chose the Tier 1 Select Agent and melioidosis pathogen, B. 104 pseudomallei, as a model organism for several reasons: i) in-105 fection occurs via environmental acquisition only, meaning 106 that AMR only arises in response to certain selective pres-107 sures (e.g. in its host during antibiotic treatment, or in the 108 environment) and is not transferred horizontally among its 109 human or animal hosts; ii) AMR in B. pseudomallei is ex-110 clusively chromosomally-encoded, rendering existing software 111 insufficient for AMR detection; and iii) AMR development in 112 B. pseudomallei results in treatment failure, higher mortality 113 rates, and limited treatment options [12] . 114 To assess the performance of ARDaP, this tool was vali-115 dated using 23 previously characterised AMR B. pseudomallei 116 strains with known antibiotic minimum inhibitory concentra-117 tions (MICs) ( Table 1) . These strains represent the spectrum 118 of known AMR determinants in B. pseudomallei [12, 24, 29-119 40] , with at least one strain being resistant towards one or 120 more of the clinically-relevant antibiotics ( Table 2) . As the 121 AMR profiles and AMR determinants for many of these strains 122 have previously been characterised, we were able to accurately 123 assess the ability of ARDaP to identify known AMR determi-124 nants, and to ignore genetic variants that do not cause AMR 125 (Table 2) . ARDaP correctly identified all AMR determinants 126 (Table 1) with 100% specificity, with the exception of one 127 false negative and three false positives. The false negative 128 result was an 800kb inversion in strain 354e, which directly 129 impacts llpE, a gene that resides between the efflux repres-130 sor gene, bpeT, and its associated efflux pump, encoded by 131 bpeEF-oprC [40] . This inversion was not detected due to limi-132 tations in short-read Illumina data that led to this structural 133 variant not easily being identified by Pindel, coupled with 134 the occurrence of this inversion outside of an AMR deter-135 minant. One of the false-positive strains, MSHR5654, was 136 predicted to be MEM resistant according to ARDaP, and 137 two other strains, MSHR5666 and MSHR5669, were predicted 138 to be DOX resistant, yet Etests showed sensitivity towards 139 these respective antibiotics. MSHR5654, which was isolated 140 from a cystic fibrosis patient with a chronic infection [30, 141 41], encodes a BpeT Thr314fs variant. Although this strain is 142 considered MEM sensitive, when compared with wild-type 143 strains, it exhibited an elevated MEM MIC (2 µg/mL) that 144 was still below the resistance threshold (3 µg/mL). bpeT is 145 a LysR-type transcriptional regulator that controls expres-146 sion of the resistance-nodulation-division (RND) efflux pump, 147 bpeEF-oprC [42] . Alterations in bpeT have previously been 148 linked with MEM resistance in MSHR1300 (4 µg/mL) [12] 149 and 354e (6 µg/mL) [12] . However, MSHR1300 also encodes 150 an AmrR K13fs variant that likely causes the MEM resistance 151 [12] , and in 354e, the 800kb inversion that displaced bpeT 152 by 800kb may also affect other AMR-conferring genes. Our 153 study supports prior work [29] suggesting that the contribu-154 tion of the bpeEF-oprC efflux pump in conferring AMR in B. 155 pseudomallei is currently poorly understood, with additional 156 192 Our study demonstrates that accurate prediction of novel 193 chromosomal AMR determinants requires cataloguing of nat-194 ural variation in the antibiotic-sensitive strain population to 195 avoid false-positive AMR calls. The inclusion of 1,040 primary 196 (i.e. predominantly pre-antibiotic treatment) B. pseudoma-197 llei genomes in our study enabled robust investigation of all 198 putative AMR determinants described in the literature to 199 date. The rationale for using a large primary isolate dataset 200 was that AMR determinants would not be present in this 201 strain cohort due to their antibiotic-sensitive nature towards 202 the drugs used to treat melioidosis, except in cases where 203 the patient had begun receiving antibiotic treatment prior 204 to primary isolate retrieval. Of the 1,040 primary strains, 205 ARDaP predicted AMR in 22 strains, with the remaining 206 strains classed as antibiotic-sensitive. The majority (17/22; 207 77%) of AMR strains possessed a Ser72Phe mutation in the 208 PenA β-lactamase (K96243 numbering: PenA S78F ; encoded 209 by BPSS0946 ), which has previously been linked to AMC 210 resistance [24, 35, 36]. To investigate further, we performed 211 MIC testing on 10 of these strains, which revealed that all 212 were sensitive towards AMC (MIC=1.5 µg/mL). These re-213 sults confirm that PenA S72F does not by itself confer AMC 214 resistance, with this variant present in the wild-type B. pseu-215 domallei population at a rate of 1.6%. Previous work has 216 suggested that either over-expression of PenA or PenA S72F 217 can lead to AMC resistance [33, 35] ; however, the exact MICs 218 differ between studies, and further complicating this issue, 219 the contribution of PenA expression differences versus enzyme 220 modifications is variable [33, 35, 45] . We therefore propose 221 that AMC resistance is conferred by both PenA S72F and PenA 222 up-regulation, the latter of which can be caused by mutations 223 within the 5' untranslated region [33] , penA CNVs [30], or 224 as-yet-undiscovered in trans regulatory changes. To account 225 for this possibility, we have included the PenA S72F variant 226 as a putative stepwise AMR variant in the ARDaP database 227 (Table 2) , with an additional PenA mutation required to defini-228 tively call AMC resistance in a given strain. We anticipate 229 that future studies will assist with elucidating the precise . In the current study, we provide further ev-246 idence that this variant does not cause IPM resistance as 247 most primary DPMS strains (789/1,040; 76%) encoded the 248 PenA T147A variant. However, it remains possible that this 249 variant confers AMR in a stepwise manner with other PenA 250 mutations, particularly those leading to penA upregulation. 251 Given that PenA T147A occurs at a very high rate in the wild-252 type B. pseudomallei population, and that it may lower the 253 barrier for IPM resistance emergence, we have included this 254 mutant as a stepwise variant in our ARDaP database to fa-255 cilitate the putative detection of potential IPM resistance, 256 especially if identified alongside penA upregulation (Table 2) . 257 It is important to note that additional work is needed to ver-258 ify this putative pathway to IPM resistance, as the basis for 259 IPM resistance in B. pseudomallei is currently speculative. 260 In addition to the IPM AMR-associated PenA variants re-261 ported in Bp1651, a novel mutation in the PenA β-lactamase, 262 PenA D239G (K96243 numbering: PenA D245G ; Bugrysheva et 263 al. numbering: PenA D240G ), has been linked to CAZ resis-264 tance (>128 µg/mL) [24] . We interrogated our DPMS primary 265 dataset for PenA D239G to determine its frequency in primary 266 Fig. 3 . Overview of the ARDaP pipeline. The user inputs assembled genome/s or raw sequencing reads, and a reference genome sequence. ARDaP then performs read alignment, read processing, mismatch realignment and variant identification. An optional phylogenetic analysis is also performed (if specified). Coverage assessment is undertaken on either single or mixed genomes (if specified), genetic variants are then annotated and AMR databases are interrogated. Finally, ARDaP produces a summary report of the detected and annotated AMR determinants for each strain (Figure 2 (Table 3) [41]. AmrAB-OprA loss-of-function variants have also 289 been described in Bp1651 (AmrB A254fs ), and the AmrB T367R 290 variant is naturally present in many Malaysian Borneo strains 291 from Sarawak [38] . Because of their unusual aminoglyco-292 side sensitivity, all AmrA and AmrB mutated strains fail to 293 grow on Ashdown's agar, which includes 4 µg/mL gentamicin 294 (GEN) for B. pseudomallei selection [48] . Given their abil-295 ity to override predicted AMR genotypes, we incorporated 296 these antimicrobial-sensitive genotypes into ARDaP to better 297 reflect the strain phenotype. These unusual variants may pro-298 vide additional treatment options for melioidosis patients who 299 otherwise could not be treated with aminoglycosides due to 300 inherent resistance to this antibiotic class. AmrA or AmrB 301 mutants are also rendered MEM-sensitive, meaning that in-302 fections with such strains are at a far lower risk of developing 303 MEM resistance than wild-type strains. The inclusion of 304 sensitivity-conferring variants is thus just as important as in-305 cluding AMR determinants, and should be a considered in all 306 15% (BPSL3085 S130L ), and 50% (AmrR ∆V62-H223 ) ( Table 4 ).
357
The high sensitivity of the penA CNVs and PenA C69Y can be ARDaP confidently identified all mixtures, albeit with varying 368 sensitivities. Further validation on specific variant mixtures 369 is recommended when new mixtures are identified to deter-370 mine their sensitivity. Deeper sequencing (e.g. 100-500x) 371 should enable more robust mixture detection at lower allele 372 frequencies.
373
The final output from ARDaP is the generation of an easy-374 to-interpret report that summarises the AMR determinants 375 and associated antibiotic phenotype/s, if applicable, for each 376 genome under investigation. This clinician-friendly report, 377 which is based on the format developed by Crisan and col-378 leagues [43], summarises AMR findings for both first-and 379 second-line antibiotic treatments (Figure 2) , and has been 380 designed to prioritise the clinical workflow. AMR results are 381 ordered hierarchically to impart relevant information at a quick 382 glance, enabling end users such as clinicians to make informed 383 decisions about patient treatment based on the reported AMR 384 profile without requiring a detailed understanding of the un-385 derlying AMR determinants and their mechanisms of action. 386 This ARDaP report also lists stepwise AMR determinants, 387 which are critical to report as they can inform early treat-388 ment shifts that minimise the risk of AMR emergence. This 389 easy-to-interpret report represents a major improvement over 390 current software for AMR annotation, which requires an in-391 timate understanding of AMR determinants and associated 392 AMR mechanisms to disambiguate technically-detailed out-393 puts. The simple and accurate AMR report produced by 394 ARDaP represents an important step towards the incorpo-395 ration of WGS as a routine tool for guiding best-practice 396 AMR stewardship and personalised treatment regimens in the 397 clinical diagnostic setting.
398

Conclusion
399
WGS is becoming a routine and essential tool for the rapid 400 detection of AMR determinants as it provides the best diag-401 nostic method to mitigate the predicted devastating impact of 402 AMR on global health in the coming decades. Whilst existing 403 software can readily detect horizontally-acquired AMR genes, 404 these tools currently have limited capacity to detect AMR 405 determinants caused by chromosomal mutation, leading to sub-406 stantial underreporting of AMR in many bacterial pathogens. 407 To overcome this major limitation in AMR research, we devel-408 oped ARDaP, which detects AMR caused by both horizontal 409 gene acquisition and chromosomal mutation events. As the 410 mechanisms by which pathogens develop AMR are diverse and 411 complex, we tailored ARDaP for the detection of >50 B. pseu-412 domallei known and novel AMR determinants, although this 413 tool has been designed for implementation with any pathogen 414 of interest. ARDaP also incorporates a mixture-aware feature 415 that enables the detection of emerging AMR determinants in 416 genomic data, which can inform early treatment shifts that will 417 ultimately improve antibiotic stewardship efforts and patient 418 survival. Our work demonstrates that novel AMR determi-419 nants can be reliably predicted from WGS data; however, large 420 collections of susceptible strains and functional verification (e.g. 421 gene knockouts, heterologous expression, or RNA sequencing) 422 are still required to validate novel AMR determinants. Finally, 423 we assert that software designed for AMR detection from WGS 424 data requires well-curated pathogen-specific databases for the 425 most accurate, comprehensive, and relevant AMR detection. 426 Of utmost importance in ongoing research efforts is to uncover 427 the myriad ways that bacteria evolve to evade antibiotics. 
